Alzheimer’s disease: future drug development and the blood-brain barrier

References

• Liu HL, Hsu PH, Lin CY, et al. Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology. 2016 Oct;281(1):99–108.
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS. 2011 Jan 18;8(1):4.
   PubMedGoogle Scholar
• Pardridge WM. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clin Pharmacol Ther. 2015 Apr;97(4):347–361.
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016 Sep 1;537(7618):50–56.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies. Expert Opin Biol Ther. 2016 Dec;16(12):1455–1468.
   PubMed Web of Science ®Google Scholar
• Atwal JK, Chen Y, Chiu C, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med. 2011 May 25;3(84):84ra43.
   PubMed Web of Science ®Google Scholar
• Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49–69.
   PubMed Web of Science ®Google Scholar
• Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci. 2003;21(3–4):79–96.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016 Jul;13(7):963–975.
   PubMed Web of Science ®Google Scholar
• Yadav DB, Maloney JA, Wildsmith KR, et al. Widespread brain distribution and activity following i.c.v. infusion of anti-beta-secretase (BACE1) in nonhuman primates. Br J Pharmacol. 2017 Nov;174(22):4173–4185.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Mundo EE, Ulufatu S, et al. Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm. 2014 May 5;11(5):1591–1598.
   PubMedGoogle Scholar
• Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004 Jul 7;24(27):6144–6151.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Cohen S, vanDyck CH, et al. A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018 May 22;90(21):e1889–e1897.
   PubMed Web of Science ®Google Scholar
• Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401-a clinical study in Alzheimer’s disease with a protofibril selective Ab antibody. Alzheimer’s Res Ther. 2016 Apr 6;8(1):14.
   PubMedGoogle Scholar
• Salloway S, Honinber LA, Cho W, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumabanti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimer’s Res Ther. 2018 Sep 19;10(1):96.
   PubMedGoogle Scholar
• Qureshi IA, Tirucherai G, Ahlijanian MK, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement. 2018;4:746–755.
   Google Scholar
• Boado RJ, Zhang Y, Zhang Y, et al. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem. 2007 Mar-Apr;18(2):447–455.
   PubMed Web of Science ®Google Scholar
• Perry RT, Collins JS, Wiener H, et al. The role of TNF and its receptors in Alzheimer’s disease. Neurobiol Aging. 2001 Nov-Dec;22(6):873–883.
   PubMed Web of Science ®Google Scholar
• Sumbria RK, Hui EK, Lu JZ, et al. Disaggregation of amyloid plaque in brain of Alzheimer’s disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol Pharm. 2013 Sep 3;10(9):3507–3513.
   PubMedGoogle Scholar
• Boado RJ, Hui EK, Lu JZ, et al. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol. 2010 Mar;146(1–2):84–91.
   PubMed Web of Science ®Google Scholar
• Chang R, Knox J, Chang J, et al. Blood-brain barrier penetrating biologic TNF-alpha inhibitor for Alzheimer’s disease. Mol Pharm. 2017 Jul 3;14(7):2340–2349.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug 8;8:495–505.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Hui EK, Lu JZ, et al. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 2010 Jun;333(3):961–969.
   PubMed Web of Science ®Google Scholar
• Chang R, Al Maghribi A, Vanderpoel V, et al. Brain penetrating bifunctional erythropoietin-transferrin receptor antibody fusion protein for Alzheimer’s disease. Mol Pharm. 2018 Nov 5;15(11):4963–4973.
   PubMedGoogle Scholar
• Cummings BJ, Cotman CW. Image analysis of beta-amyloid load in Alzheimer’s disease and relation to dementia severity. Lancet. 1995 Dec 9;346(8989):1524–1528.
   PubMed Web of Science ®Google Scholar
• Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama. 2000 Mar 22–29;283(12):1571–1577.
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984 May 16; 120(3):885–890.
   PubMed Web of Science ®Google Scholar
• Brendza RP, Bacskai BJ, Cirrito JR, et al. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005 Feb;115(2):428–433.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Dibello V, et al. Are antibodies directed against amyloid-beta (Abeta) oligomers the last call for the Abeta hypothesis of Alzheimer’s disease? Immunotherapy. 2019 Jan;11(1):3–6.
   PubMed Web of Science ®Google Scholar
• Giugliani R, Giugliani L, de Oliveira Poswar F, et al. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1–2 trial. Orphanet J Rare Dis. 2018 Jul 5;13(1):110.
   PubMedGoogle Scholar
• Okuyama T, Eto Y, Sakai N, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial. Mol Ther. 2019 Feb 6;27(2):456–464.
   PubMed Web of Science ®Google Scholar